

Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn20>

A NEW SYNTHETIC METHODOLOGY FOR TIAZOFURIN

Kanda S. Ramasamy^a & Johnson Y. N. Lau^a

^a ICN Pharmaceuticals, Inc. , 3300 Hyland Avenue, Costa Mesa, California, 92626, U.S.A.

Published online: 07 Feb 2007.

To cite this article: Kanda S. Ramasamy & Johnson Y. N. Lau (2001) A NEW SYNTHETIC METHODOLOGY FOR TIAZOFURIN, Nucleosides, Nucleotides and Nucleic Acids, 20:4-7, 1329-1331, DOI: [10.1081/NCN-100002548](https://doi.org/10.1081/NCN-100002548)

To link to this article: <http://dx.doi.org/10.1081/NCN-100002548>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

A NEW SYNTHETIC METHODOLOGY FOR TIAZOFURIN

Kanda S. Ramasamy* and Johnson Y. N. Lau

ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa,
California 92626

ABSTRACT

A new synthesis of tiazofurin is described from 2,3-*O*-isopropylidene-5-*O*-benzoyl- β -D-ribofuranosyl cyanide.

Tiazofurin (1) [1, 2-(β -D-ribofuranosyl)thiazole-4-carboxamide]] attracted considerable attention because of its significant activity against both human lymphoid (2), and lung tumor cell lines (3), and murine-implanted human ovarian cancers (4). The biological effects also include its efficacy in the treatment of acute myeloid leukemia (5). In addition, recent studies of tiazofurin have generated even more interest as a possible treatment for patients with chronic myeloid leukemia (CML) in blast crisis (6). Tiazofurin shows activity by inhibition of inosine monophosphate dehydrogenase (IMPDH), by forming the corresponding NAD-like tiazofurin adenine dinucleotide (TAD), which induces the shutdown of guanine nucleotide synthesis (7).

Several methods are known in the literature (8–14) for the synthesis of tiazofurin. But, most of them suffer from low yield, give a mixture of products (2 & 3) and utilize hydrogen sulfide gas, which is environmentally unsafe on large-scale production. The biological importance of tiazofurin and the problems associated with the reported methods encouraged us to discover a new synthetic methodology for the preparation of tiazofurin. In this communication, we describe a new method for the synthesis of tiazofurin, which eliminates the use of H₂S gas and the by-products.

*Corresponding author.





Figure 1.

The synthetic route for tiazofurin is shown in Scheme 1. We elected to use the known 1-cyano-2,3-*O*-isopropylidene-5-*O*-benzoyl- β -D-ribofuranose (**4**) (15) as our starting material. Reaction of **4** with cysteine ethyl ester hydrochloride in the presence of triethylamine at room temperature gave readily thiazoline intermediate **5** in 90% yield. ^1H NMR spectrum of **5** showed the presence of a thiazoline methylene group at δ 3.61 and a methine proton at δ 5.08 which are characteristic of Δ^2 -thiazolines (16). Oxidation of **5** with activated MnO_2 (17) in benzene afforded a clean product **6**. Observation of the NMR spectrum of **6** indicated the absence of the methylene and the methine protons of the thiazoline ring and the presence of a vinyl



Scheme 1. Reagents and conditions: i) Cysteine ethyl ester HCl/TEA; ii) MnO_2 /Benzene; iii) 90%TFA; iv) NH_3 /MeOH.

proton, which accounted for the dehydrogenation of **5**. Exposure of **6** to 90% TFA for 1 h at room temperature gave ethyl 2-(5'-*O*-benzoyl- β -D-ribofuranosyl)thiazole-4-carboxylate (**7**) in 98% yield. Finally, treatment of **7** with methanolic ammonia at room temperature for 12 h afforded tiazofurin in 90% yield.

There are several merits to the present method. First, it avoided the use of toxic mercuric salt and hydrogen sulfide, which are environmentally unsafe. Secondly, the formation of the side products **2** and **3** were eliminated, and the yield of tiazofurin is substantially improved over previous methods. Third, the present method does not require column chromatographic purification, thereby reducing the cost of production of the drug. Fourth, the same methodology could be used to construct other five membered C-nucleosides by replacing sulfur in **1** with heteroatoms such as oxygen, selenium or nitrogen. The synthesis of other such C-nucleosides are in progress and their results will be reported elsewhere.

In summary, we have developed a safe, convenient and higher yielding new methodology for the synthesis of the important antitumor agent tiazofurin.

REFERENCES

1. Tiazofurin is the generic name approved by the United States Adopted Name Council.
2. Earle, M. F.; Glazer, R. I. *Cancer Res.* **1983**, *43*, 133.
3. Carnex, D. N.; Abluwalia, G. S.; Jayaram, H. N.; Cooney, D. A.; Johns, D. G. *J. Clin. Invest.* **1985**, *75*, 175.
4. Micha, J. P.; Kucera, P. R.; Preve, C. N.; Rettenmaier, M. A.; Stratton, J. A.; DiSaia, P. J. *Gynecol. Oncol.* **1985**, *21*, 351.
5. Tricot, G. T.; Jayaram, H. N.; Nichols, C. R.; Pennington, K.; Lapis, E.; Weber, G.; Hoffman, R. *Cancer Res.* **1997**, *47*, 4988.
6. Weber, G. *United States Patent* 5, 405,837 (1995).
7. Olah, E.; Natusmeda, Y.; Ikegami, T.; Kote, Z.; Horanyi, M.; Szelenye, J.; Paulik, E.; Kremmer, T.; Hollan, S. R.; Sugar, J.; Weber, G. *Proc. Natl. Acad. Sci. USA.* **1988**, *85*, 6533.
8. Srivastava, P. C.; Pickering, M. V.; Allen, L. B.; Streeter, D. G.; Campbell, M. T.; Witkowski, J. T.; Sidwell, R. W.; Robins, R. K. *J. Med. Chem.* **1977**, *20*, 256.
9. Fuertes, M.; Garcia-Lopez, T.; Garcia-Munoz, G.; Stud, M. *J. Org. Chem.* **1976**, *41*, 4074.
10. Hennen, W. J.; Hinshaw, B. C.; Riely, T. A.; Wood, S. G.; Robins, R. K. *J. Org. Chem.* **1985**, *50*, 1741.
11. Bimwala, R. M.; Vogel, P. *Helv. Chim. Acta* **1989**, *72*, 1825.
12. Humber, D. C.; Mulholland, K. R.; Stoodley, R. J. *J. Chem. Soc. Perkin Trans. I* **1990**, 283.
13. Parsons, J. L.; Vizine, D.; Summer, M.; Marathe, S.; Dubicki, H. *United States Patent* 4,451,648 (1984).
14. Ramasamy, K. S.; Averett, D. *Nucleosides & Nucleotides* **1999**, *18*, 2425.
15. Cook, P. D.; McNamara, D. J. *J. Heterocycl. Chem.* **1986**, *23*, 155.
16. Minster, D. K.; Jordis, U.; Evans, D. L.; Hecht, S. M. *J. Org. Chem.* **1978**, *43*, 1624.
17. Ishihara, H.; Shimura, K. *FEBS Lett.* **1988**, *226*, 319.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002548>